Iovance Biotherapeutics, Inc. $IOVA Shares Acquired by Tema ETFs LLC

Tema ETFs LLC lifted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 52.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 280,048 shares of the biotechnology company’s stock after buying an additional 95,933 shares during the quarter. Tema ETFs LLC owned approximately 0.06% of Iovance Biotherapeutics worth $1,165,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of IOVA. Centurion Wealth Management LLC grew its position in Iovance Biotherapeutics by 18.5% in the 2nd quarter. Centurion Wealth Management LLC now owns 69,168 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 10,784 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Iovance Biotherapeutics by 100.0% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 818,913 shares of the biotechnology company’s stock valued at $3,407,000 after purchasing an additional 409,449 shares during the period. Mirador Capital Partners LP boosted its stake in shares of Iovance Biotherapeutics by 0.7% in the second quarter. Mirador Capital Partners LP now owns 1,080,288 shares of the biotechnology company’s stock valued at $4,494,000 after purchasing an additional 7,052 shares during the period. Optiver Holding B.V. grew its holdings in shares of Iovance Biotherapeutics by 24.0% in the first quarter. Optiver Holding B.V. now owns 36,660 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 7,092 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in Iovance Biotherapeutics by 55.1% during the 1st quarter. Janus Henderson Group PLC now owns 141,672 shares of the biotechnology company’s stock worth $498,000 after buying an additional 50,331 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Citizens Jmp raised their price target on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Robert W. Baird set a $6.00 target price on Iovance Biotherapeutics in a research note on Friday, August 7th. Chardan Capital cut their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Barclays increased their price target on Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Iovance Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $8.00.

Iovance Biotherapeutics Trading Down 3.3%

Shares of IOVA opened at $6.52 on Friday. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -8.93 and a beta of 0.71. The firm’s fifty day simple moving average is $4.60 and its 200-day simple moving average is $3.92. Iovance Biotherapeutics, Inc. has a twelve month low of $1.76 and a twelve month high of $6.92.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. The firm had revenue of $198.63 million during the quarter, compared to the consensus estimate of $87.83 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The company’s revenue was up 65.7% compared to the same quarter last year. On average, analysts predict that Iovance Biotherapeutics, Inc. will post -0.5 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.